Mirum's Explosive 89% Rally Masks a Smart Portfolio Pivot by Major Biotech Investor

The Real Story Behind the Share Reduction

Eventide Asset Management, the Boston-based fund, has sent interesting signals in its latest SEC filing. The firm trimmed its Mirum (NASDAQ:MIRM) position by divesting one-hundred-fifteen thousand shares during Q3, yet the overall stake’s market value actually expanded by approximately $50.70 million. This apparent contradiction reveals a nuanced investment approach rather than a retreat.

Position Growth Driven by Clinical Validation

As of September 30, Eventide maintains 2.52 million shares worth roughly $184.92 million—now representing 3.04% of the fund’s assets under management and ranking as its second-largest equity holding. The dramatic 89% year-to-date surge in Mirum’s stock price explains why fewer shares translated into greater portfolio value. Trading at $79.26 per share Friday, the stock substantially outpaced the S&P 500’s 15% gain.

This dynamic—selling into strength while letting a position grow substantially—reflects calculated conviction rather than profit-taking. The fund’s willingness to maintain such significant exposure to a biotech name already appreciating sharply suggests confidence in the company’s commercial inflection.

Financial Momentum Justifies the Confidence

Mirum’s recent operational performance provides concrete justification. Third-quarter revenue reached $133 million, representing 47% growth, while management elevated full-year guidance to $500-510 million. This acceleration stems from expanding sales of LIVMARLI, its lead therapeutic targeting rare cholestatic liver diseases, alongside growing bile acid medicine revenue.

The company’s balance sheet strengthens the thesis. Cash and investments reached $378 million by quarter-end, providing sufficient dry powder to advance multiple pipeline programs without immediate dilution risks. With a market capitalization of $4.10 billion and trailing twelve-month revenue of $471.79 million, the valuation reflects the market’s recognition of Mirum’s transition from development-stage promise to revenue-generating reality.

Rare Disease Focus Provides Defensive Positioning

Mirum specializes in therapies for debilitating orphan diseases with limited treatment options. LIVMARLI targets Alagille syndrome and progressive familial intrahepatic cholestasis, conditions affecting small patient populations where unmet medical needs remain severe. Volixibat expands the company’s reach into additional rare hepatic indications.

This strategic niche positioning creates competitive advantages. High-value, underserved populations generate strong product economics, while rare disease specialists face less direct competition than mainstream pharma players.

Broader Portfolio Context

Within Eventide’s holdings, Mirum now occupies a prominent position alongside other growth-oriented healthcare investments:

• Guardant Health (GH): $207.51 million (3.4% of AUM)
• Mirum (MIRM): $184.92 million (3.0% of AUM)
• Xometry (XMTR): $169.87 million (2.8% of AUM)
• Thermotrex (TT): $168.00 million (2.8% of AUM)
• Insmed (INSM): $144.74 million (2.4% of AUM)

The concentration underscores the manager’s preference for companies demonstrating clear commercial traction rather than speculative binary outcomes.

The Investment Takeaway

The share reduction represents portfolio rebalancing amid concentrated positioning, not conviction erosion. When a manager allows a stock position to appreciate substantially and maintains significant exposure post-gain, the message centers on business fundamentals rather than trading cycles. Mirum’s demonstrated revenue acceleration, cash generation, and rare disease tailwinds suggest this positioning may have room to run.